Parkinson's Disease-Cognitive Rating Scale (PD-CRS): Normative Data and Mild Cognitive Impairment Assessment in Brazil.
Parkinson's Disease‐Cognitive Rating Scale
Parkinson's disease
cognitive screening
mild cognitive impairment
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
04
05
2022
revised:
10
12
2022
accepted:
29
12
2022
pmc-release:
25
02
2024
entrez:
23
3
2023
pubmed:
24
3
2023
medline:
24
3
2023
Statut:
epublish
Résumé
The Parkinson's Disease-Cognitive Rating Scale (PD-CRS) assesses posterior-cortical and frontal-subcortical cognitive functioning and distinguishes mild cognitive impairment in Parkinson's disease (PD-MCI); however, it was not evaluated in Brazil. To investigate PD-CRS's reliability, validity, normative data, and accuracy for PD-MCI screening in Brazil. The effects of age, education, and sex on PD-CRS scores were explored. The instrument was tested in 714 individuals (53% female, 21-94 years), with a broad range of education and no neurodegenerative disorder. Trail Making, Consonant Trigrams, Five-Point, and semantic fluency tests were administered for comparison. A second study enrolled patients with PD and intact cognition (n = 44, 59.75 ± 10.79 years) and with PD-MCI (n = 25, 65.76 ± 10.33 years) to investigate criterion validity. PD-CRS subtests were compared with the Cambridge Automated Neuropsychological Battery memory and executive tasks. PD-CRS was unidimensional and reliable (McDonald's ω = 0.83). Using robust multiple regressions, age, and education predicted the total and derived scores in the normative sample. At the 85-point cutoff, PD-MCI was detected with 68% sensitivity and 86% specificity (area under the curve = 0.870). PD-CRS scores strongly correlated with executive and verbal/visual memory tests in both normative and clinical samples. This study investigated the applicability of PD-CRS in the Brazilian context. The scale seems helpful in screening for PD-MCI, with adequate internal consistency and construct validity. The PD-CRS variance is influenced by age and educational level, a critical issue for cognitive testing in countries with educational and cultural heterogeneity.
Sections du résumé
Background
UNASSIGNED
The Parkinson's Disease-Cognitive Rating Scale (PD-CRS) assesses posterior-cortical and frontal-subcortical cognitive functioning and distinguishes mild cognitive impairment in Parkinson's disease (PD-MCI); however, it was not evaluated in Brazil.
Objectives
UNASSIGNED
To investigate PD-CRS's reliability, validity, normative data, and accuracy for PD-MCI screening in Brazil.
Methods
UNASSIGNED
The effects of age, education, and sex on PD-CRS scores were explored. The instrument was tested in 714 individuals (53% female, 21-94 years), with a broad range of education and no neurodegenerative disorder. Trail Making, Consonant Trigrams, Five-Point, and semantic fluency tests were administered for comparison. A second study enrolled patients with PD and intact cognition (n = 44, 59.75 ± 10.79 years) and with PD-MCI (n = 25, 65.76 ± 10.33 years) to investigate criterion validity. PD-CRS subtests were compared with the Cambridge Automated Neuropsychological Battery memory and executive tasks.
Results
UNASSIGNED
PD-CRS was unidimensional and reliable (McDonald's ω = 0.83). Using robust multiple regressions, age, and education predicted the total and derived scores in the normative sample. At the 85-point cutoff, PD-MCI was detected with 68% sensitivity and 86% specificity (area under the curve = 0.870). PD-CRS scores strongly correlated with executive and verbal/visual memory tests in both normative and clinical samples.
Conclusions
UNASSIGNED
This study investigated the applicability of PD-CRS in the Brazilian context. The scale seems helpful in screening for PD-MCI, with adequate internal consistency and construct validity. The PD-CRS variance is influenced by age and educational level, a critical issue for cognitive testing in countries with educational and cultural heterogeneity.
Identifiants
pubmed: 36949793
doi: 10.1002/mdc3.13657
pii: MDC313657
pmc: PMC10026291
doi:
Types de publication
Journal Article
Langues
eng
Pagination
452-465Informations de copyright
© 2023 International Parkinson and Movement Disorder Society.
Références
Parkinsons Dis. 2020 Feb 19;2020:5289136
pubmed: 32148754
Rev Saude Publica. 1995 Oct;29(5):355-63
pubmed: 8731275
Disabil Rehabil. 2022 May;44(10):2091-2098
pubmed: 32924645
Eur Neurol. 2018;79(3-4):206-210
pubmed: 29597229
Parkinsonism Relat Disord. 2013 Jan;19(1):115-9
pubmed: 22981311
Mov Disord. 2013 Dec;28(14):1972-9
pubmed: 24123267
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Mov Disord. 2018 Nov;33(11):1750-1759
pubmed: 30216541
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Mov Disord. 2018 Feb;33(2):208-218
pubmed: 29168899
Arq Neuropsiquiatr. 2019 Nov;77(11):775-781
pubmed: 31826133
Arch Clin Neuropsychol. 1997;12(1):29-40
pubmed: 14588432
Neurobiol Dis. 2012 Jun;46(3):590-6
pubmed: 22484304
Nat Rev Neurol. 2017 Apr;13(4):217-231
pubmed: 28257128
Mov Disord. 2008 May 15;23(7):998-1005
pubmed: 18381647
Mov Disord. 2013 May;28(5):626-33
pubmed: 23520128
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Neurodegener Dis. 2013;11(2):79-92
pubmed: 23038420
Neurology. 2009 Nov 24;73(21):1738-45
pubmed: 19933974
Neurol Sci. 2017 May;38(5):845-853
pubmed: 28224328
Dement Neuropsychol. 2014 Jan-Mar;8(1):26-31
pubmed: 29213876
Assessment. 2016 Apr;23(2):191-202
pubmed: 25940350
Arq Neuropsiquiatr. 2012 Mar;70(3):175-9
pubmed: 22286401
Cogn Behav Neurol. 2012 Jun;25(2):72-6
pubmed: 22596112
J Neurol Sci. 2020 Dec 15;419:117177
pubmed: 33068906
Dementia. 1994 Sep-Oct;5(5):266-81
pubmed: 7951684
Parkinsonism Relat Disord. 2017 Oct;43:73-77
pubmed: 28754233
Dement Neuropsychol. 2015 Jul-Sep;9(3):258-264
pubmed: 29213970
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Exp Psychol. 1959 Sep;58:193-8
pubmed: 14432252
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Mov Disord. 2015 Mar;30(3):402-6
pubmed: 25449653
J Consult Psychol. 1955 Oct;19(5):393-4
pubmed: 13263471
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Dement Neuropsychol. 2020 Jan-Mar;14(1):14-23
pubmed: 32206193
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Clin Exp Neuropsychol. 2011 Jun;33(5):505-22
pubmed: 21391011
Int Psychogeriatr. 2009 Dec;21(6):1081-7
pubmed: 19619390
Neurology. 2010 Nov 9;75(19):1717-25
pubmed: 21060094
Eur Neurol. 2017;77(5-6):246-252
pubmed: 28319952
J Int Neuropsychol Soc. 2009 Nov;15(6):1012-22
pubmed: 19796440
Mov Disord Clin Pract. 2018 Mar 23;5(3):259-264
pubmed: 30363408
Mov Disord. 2007 Oct 15;22(13):1901-11
pubmed: 17674410
PLoS One. 2012;7(9):e46080
pubmed: 23029395
Clin Neuropsychol. 2015;29(6):836-46
pubmed: 26513484
Mov Disord. 2013 Sep;28(10):1376-83
pubmed: 23873810
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
Percept Mot Skills. 1982 Dec;55(3 Pt 1):839-44
pubmed: 7162920
Hum Brain Mapp. 2002 Jan;15(1):1-25
pubmed: 11747097
Mov Disord. 2009 Aug 15;24(11):1641-9
pubmed: 19514014
Neurology. 2010 Sep 21;75(12):1062-9
pubmed: 20855849
Psychol Assess. 2005 Sep;17(3):336-44
pubmed: 16262459
Neurol Sci. 2014 Apr;35(4):537-44
pubmed: 24221858
Arq Neuropsiquiatr. 2003 Sep;61(3B):777-81
pubmed: 14595482
Mov Disord. 2012 Mar;27(3):349-56
pubmed: 22275317